Agios Pharmaceuticals to Present Preclinical Research at the 2013 American Society of Hematology Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 7, 2013--
“We are eager for the opportunity to present preclinical data on our three lead programs at this year’s ASH Annual Meeting, which gathers many of the world’s leading hematologists,” said
The schedule for Agios’ presentations is as follows:
Date & Time: |
Monday, December 9, 2013, 8:15 a.m. CT | ||
Session: |
615. Acute Myeloid Leukemia: Therapy, excluding Transplantation: | ||
Translational Studies | |||
Presentation Title: |
AG-221 offers a survival advantage in a primary human IDH2 mutant AML xenograft model | ||
| |||
Presenter: |
Katharine Yen, Ph.D., director, biology | ||
Date & Time: |
Monday, December 9, 2013, 6:00 – 8:00 p.m. CT | ||
Session: |
615. Acute Myeloid Leukemia: Therapy, excluding Transplantation: | ||
|
Poster III | ||
Poster Title: |
IDH1 mutant inhibitor induces cellular differentiation and offers a combination benefit | ||
with Ara-C in a primary human IDH1 mutant AML xenograft model | |||
Presenter: |
Fang Wang, Ph.D., associate director, biology | ||
Date & Time: |
Sunday, December 8, 2013, 6:30 – 8:30 p.m. CT | ||
Session: |
101. Red Cells and Erythropoiesis, Structure and Function, Metabolism | ||
and Survival, Excluding Iron: Poster II | |||
Poster Title: |
Small molecule activation of pyruvate kinase normalizes metabolic activity in red cells | ||
from patients with pyruvate kinase deficiency-associated hemolytic anemia | |||
Presenter: |
Charles Kung, Ph.D., associate director, translational biology | ||
About
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Agios’ expectations and beliefs about: the potential of IDH1/IDH2 and pyruvate kinase R mutations as therapeutic targets; the potential benefits of Agios’ product candidates targeting IDH1/IDH2 or pyruvate kinase R mutations, including AG-221 and AG-348; and the benefit of its strategic plans and focus. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios’ current expectations and beliefs, including the risks described under the caption “Risk Factors” included in Agios’ Quarterly Report on Form 10-Q for the quarter ended
Source:
Agios Pharmaceuticals, Inc.
Media Contact:
Dan Budwick, 973-271-6085
dan@purecommunicationsinc.com
or
Investor Contact:
Glenn Goddard
investors@agios.com